SEARCH

SEARCH BY CITATION

Bibliography

  • 1
    Bodger K, Daly MJ & Heatley RV. Clinical economics review: Helicobacter pylori-associated peptic ulcer disease. Aliment Pharmacol Ther 1997; 11: 27382.
  • 2
    Deltenre MA. Economics of Helicobacter pylori eradication therapy. European J Gastroenterol Hepatol 1997; 9(Suppl. 1): S23S26.
  • 3
    Phull PS, Ryder SD, Halliday D, Price AB, Levi AJ & Jacyna MR. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease; a community-based study. Postgraduate Med J 1995; 71: 4138.
  • 4
    Marshall BJ & Warren JR. Unidentified curved bacili in the stomach of patients with gastritis and peptic ulceration. Lancet 1983; i: 13115.
  • 5
    Peterson WL, Ciociola A, Sykes DL, Mcsorley DJ & Webb DD and the RBC H. Pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 1996; 10: 25161.
  • 6
    McColl KEL. The role of H. pylori eradication in the management of acute bleeding peptic ulcer. European J Gastroenterol Hepatol 1995; 7: 7535.
  • 7
    Veldhuyzen Zanten SJO & Sherman PM. Indications for treatment of Helicobacter pylori infection: a systematic overview. Can Med Assoc J 1994; 150: 18998.
  • 8
    Farmaindustria. Anuario de la sanidad y del medicamento en España, 1997. El Médico 1997; 636 (Suppl.): 197212.
  • 9
    Jovell AJ, Aymerich M, García-Altés A & Serra-Prat M. Guia de pràctica clínica del tractament eradicador de la infecció per Helicobacter Pylori associada a úlcera duodenal en l’atenció primària. Barcelona: Agència d’Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya, 1998.
  • 10
    Scottish Intercollegiate Guidelines Network. Helicobacter pylori. Eradication in Dyspeptic Disease. Edinburgh: SIGN, 1996.
  • 11
    Scottish Health Purchasing Information Center. Dyspepsia, Peptic Ulcer and Helicobacter pylori. Aberdeen: SHPIC, 1996.
  • 12
    Gisbert JP, Boixeda D & Martín de Argila C, et al. Nuevas terapias triples de una semana de duración con metronidazol para la erradicación de Helicobacter pylori: claritromicina o amoxicilina como segundo antibiótico. Med Clínica (Bar) 1998; 110: 15.
  • 13
    Veldhuyzen Zanten SJO, Bradette M & Farley A, et al. The Du-mach study: Eradication of Helicobacter pylori, ulcer healing and relapse in duodenal ulcer patients. Omeprazole and clarithromycin in combination with either amoxicillin or metronidazole. Gut 1997.
  • 14
    Lind T, Van Veldhuyzen Zanten S & Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials. MACH I Study. Helicobacter 1996; 1: 13844.
  • 15
    Pieramico O, Zanetti MV & Innerhofer M. Omeprazole-based dual and triple therapy for the eradication of H. pylori infection in peptic ulcer disease. Gastroenterology 1996; 110: A229A229(Abstract).
  • 16
    Sito E, Konturek PC & Bielanski W, et al. One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients. J Physiol Pharmacol 1996; 47: 2218.
  • 17
    Forné M, Viver JM, Espinos JC, Coll I, Tresserra F & Garau J. Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. Am J Gastroenterol 1995; 90: 71821.
  • 18
    Fukuda Y, Yamamoto I, Okui M, Tonokatsu Y, Tamura K & Shimoyama T. Combination therapy with mucosal protective agent for the eradication of Helicobacter pylori. European J Gastroenterol Hepatol 1995; 7(Suppl. 1): S45S47.
  • 19
    Kuipers EJ, Thijs JC & Festen HMP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 5969.
  • 20
    Mur M, Gimeno E, Guerrero L, Cabeza F & Sáinz R. Prevalencia del Helicobacter pylori en patología gástrica en Aragón. Revista Española Enfermedades Digestivas 1992; 82: 3116.
  • 21
    Tovey FI & Hobstein M. Is Helicobacter pylori the primary cause of duodenal ulceration? J Gastroenterol Hepatol 1999; 14: 10536.
  • 22
    DOGC. Ordre del 23 de desembre de 1997, per la qual es fixen per a l’any 1997 els valors de les unitats de pagament per a la contraprestació de la realització de proves de suport diagnòstiques practicades pels centres hospitalaris per a malalts aguts en règim de concert amb el Servei Català de la Salut. Diari Oficial de la Generalitat de Catalunya 1997; 2547: 15 0826.
  • 23
    DOGC. Ordre del 29 de setembre de 1997, per la qual s’aproven els preus públics corresponents als serveis que presta l’Institut Català de la Salut. Diari Oficial de la Generalitat de Catalunya 1997; 2504: 12 14954.
  • 24
    Vademecum Internacional. Especialidades Farmacéuticas Y Biológicas, Productos Y Artículos de Farmacia, Métodos de Diagnóstico, 38th edition. Madrid: Medicom, S.A., 1997.
  • 25
    Brian Fennerty M, Kovacs TOG & Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158: 16516.
  • 26
    Imperiale TF, Speroff T, Cebul RD & McCullough AJ. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123: 66572.
  • 27
    Duggan AE, Tolley K, Hawkey CJ & Logan RFA. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. Br Med J 1998; 316: 164854.
  • 28
    Ebell MH, Warbasse L & Brenner C. Evaluation of the dyspeptic patient: a cost-utility study. J Family Prac 1997; 44: 54555.
  • 29
    Ofman JJ, Etchason J, Fullerton S, Kahn KL & Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 1997; 126: 28091.
  • 30
    Veldhuyzen Zanten SJO. A systematic overview (meta-analysis) of outcome measures in Helicobacter pylori gastritis trials and functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl.): 403.
  • 31
    Aymerich M, García-Altés A & Jovell AJ. Revisió de l’evidència científica de les implicacions clíniques i econòmiques de la resistència bacteriana a la vancomicina. Barcelona: Agència d’Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya, gener 1998.
  • 32
    Aymerich M, García-Altés A & Jovell AJ. Las resistencia bacterianas: algo más que un problema clínico? La resistencia del enterococo a la vancomicina como ejemplo. Med Clínica (Bar) 1999; 112: 5535.
  • 33
    Pérez Mota A. Helicobacter pylori Y Patología Gástrica. 1997.
  • 34
    Thijs JC, Zwet AA & Thijs WJ, et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accurancy, without selecting a single test as the gold standard. Am J Gastroenterol 1996; 91: 21259.
  • 35
    Dill S, Payne-James JJ & Misiewicz JJ, et al. Evaluation of 13C-urea breath test in the detection of Helicobacter pylori and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia. Gut 1990; 31: 123741.
  • 36
    Marshall BJ, Plankey MW & Hoffman SR, et al. A 20 minutes breath test for Helicobacter pylori. Am J Gastroenterol 1991; 86: 43845.
  • 37
    Henze E, Malfertheiner P, Clausen M, Clausen M, Burkhardt H & Adam WE. Validation of a simplified carbon-14-urea breath test for routine use for detection of Helicobacter pylori noninvasively. J Nuclear Med 1990; 31: 19404.
  • 38
    Loy CT, Irwing LM, Katelaris PH & Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accurancy? A meta-analysis. Am J Gastroenterol 1996; 91: 113844.
  • 39
    Weiss J, Mecca J, Da Silva E & Gassner D. Comparison of PCR and other diagnostic techniques for detection of Helicobacter pylori infection in dyspeptic patients. J Clin Microbiol 1994; 32: 16638.
  • 40
    Sainz S, Mirelis B, González D, Sancho FJ & Monés J. Diagnóstico de la infección por Campylobacter pylori en la mucosa gástrica: aspectos histológicos y microbiológicos. Med Clínica 1990; 94: 5613.
  • 41
    Morris A, Ali MR, Brown P, Lane M & Patton K. Campylobacter pylori infection in biopsy specimens of gastric antrum: Laboratory diagnosis and estimation of sampling error. J Clin Pathol 1989; 42: 72732.
  • 42
    Schnell GA & Schubert TT. Usefulness of culture, histology and urease testing in the detection of Campylobacter pylori. Am J Gastroenterol 1989; 84: 1337.
  • 43
    Thillainayagam AV, Arvind AS & Cook RS, et al. Diagnostic efficiency of an ultrarapid endoscopy room test for Helicobacter pylori. Gut 1991; 32: 4679.